MAPT and Alzheimer disease: This is further supported by substantial longitudinal evidence demonstrating that individuals with SCD have a heightened risk of progressing to MCI and dementia and are also more likely to have AD-related biomarkers such as amyloid-β accumulation and tau protein abnormalities [3,4,5].